Cargando…

Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)

Pancreatic neuroendocrine tumours (panNET) are heterogeneous neoplasms usually characterised by slow growth and secretion of hormones, which often cause symptoms. The effect of these symptoms on quality of life (QoL) has not previously been examined in detail. EORTC (European Organisation for Resear...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramage, John K., Friend, Elizabeth, Randell, Jordan, KING, Barbara, Fernandez Ortega, Paz, McNamara, Mairéad G., Kaltsas, Gregory, Falconi, Massimo, Cwikla, Jaroslav, Capdevila, Jaume, Grozinsky‐Glasberg, Simona, Mandair, Dalvinder, Gamper, Eva, Srirajaskanthan, Raj, O Weickert, Martin, Gray, Debra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285342/
https://www.ncbi.nlm.nih.gov/pubmed/35156246
http://dx.doi.org/10.1111/jne.13097
_version_ 1784747754856120320
author Ramage, John K.
Friend, Elizabeth
Randell, Jordan
KING, Barbara
Fernandez Ortega, Paz
McNamara, Mairéad G.
Kaltsas, Gregory
Falconi, Massimo
Cwikla, Jaroslav
Capdevila, Jaume
Grozinsky‐Glasberg, Simona
Mandair, Dalvinder
Gamper, Eva
Srirajaskanthan, Raj
O Weickert, Martin
Gray, Debra
author_facet Ramage, John K.
Friend, Elizabeth
Randell, Jordan
KING, Barbara
Fernandez Ortega, Paz
McNamara, Mairéad G.
Kaltsas, Gregory
Falconi, Massimo
Cwikla, Jaroslav
Capdevila, Jaume
Grozinsky‐Glasberg, Simona
Mandair, Dalvinder
Gamper, Eva
Srirajaskanthan, Raj
O Weickert, Martin
Gray, Debra
author_sort Ramage, John K.
collection PubMed
description Pancreatic neuroendocrine tumours (panNET) are heterogeneous neoplasms usually characterised by slow growth and secretion of hormones, which often cause symptoms. The effect of these symptoms on quality of life (QoL) has not previously been examined in detail. EORTC (European Organisation for Research and Treatment of Cancer) guidelines were followed in phases 1–3 to produce a potential module of questions usable for trials in panNET, focusing on three common types of panNET. For two less common types, a list of symptoms was constructed. Following an extensive literature search and phase 1a interviews with patients and healthcare workers, a long list of potential issues (169) was obtained. This list was shown to 12 patients from three countries in phase 1b interviews to check that no items were missed. The list was reduced to 57 issues. The list of issues was converted to questions, mainly from existing validated questions within the EORTC item library. The list of questions was then used in a phase 3 international study in eight countries using seven languages. A provisional module of 24 items is presented for use in nonfunctioning panNET, gastrinoma and insulinoma. This module increases knowledge concerning QoL in this condition and may be a useful adjunct in clinical trials. A phase 4 trial is being considered for validation of this questionnaire.
format Online
Article
Text
id pubmed-9285342
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92853422022-07-15 Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module) Ramage, John K. Friend, Elizabeth Randell, Jordan KING, Barbara Fernandez Ortega, Paz McNamara, Mairéad G. Kaltsas, Gregory Falconi, Massimo Cwikla, Jaroslav Capdevila, Jaume Grozinsky‐Glasberg, Simona Mandair, Dalvinder Gamper, Eva Srirajaskanthan, Raj O Weickert, Martin Gray, Debra J Neuroendocrinol Translational and Clinical Neuroendocrinology Pancreatic neuroendocrine tumours (panNET) are heterogeneous neoplasms usually characterised by slow growth and secretion of hormones, which often cause symptoms. The effect of these symptoms on quality of life (QoL) has not previously been examined in detail. EORTC (European Organisation for Research and Treatment of Cancer) guidelines were followed in phases 1–3 to produce a potential module of questions usable for trials in panNET, focusing on three common types of panNET. For two less common types, a list of symptoms was constructed. Following an extensive literature search and phase 1a interviews with patients and healthcare workers, a long list of potential issues (169) was obtained. This list was shown to 12 patients from three countries in phase 1b interviews to check that no items were missed. The list was reduced to 57 issues. The list of issues was converted to questions, mainly from existing validated questions within the EORTC item library. The list of questions was then used in a phase 3 international study in eight countries using seven languages. A provisional module of 24 items is presented for use in nonfunctioning panNET, gastrinoma and insulinoma. This module increases knowledge concerning QoL in this condition and may be a useful adjunct in clinical trials. A phase 4 trial is being considered for validation of this questionnaire. John Wiley and Sons Inc. 2022-02-13 2022-04 /pmc/articles/PMC9285342/ /pubmed/35156246 http://dx.doi.org/10.1111/jne.13097 Text en © 2022 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Translational and Clinical Neuroendocrinology
Ramage, John K.
Friend, Elizabeth
Randell, Jordan
KING, Barbara
Fernandez Ortega, Paz
McNamara, Mairéad G.
Kaltsas, Gregory
Falconi, Massimo
Cwikla, Jaroslav
Capdevila, Jaume
Grozinsky‐Glasberg, Simona
Mandair, Dalvinder
Gamper, Eva
Srirajaskanthan, Raj
O Weickert, Martin
Gray, Debra
Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)
title Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)
title_full Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)
title_fullStr Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)
title_full_unstemmed Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)
title_short Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)
title_sort development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the pannet module)
topic Translational and Clinical Neuroendocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285342/
https://www.ncbi.nlm.nih.gov/pubmed/35156246
http://dx.doi.org/10.1111/jne.13097
work_keys_str_mv AT ramagejohnk developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT friendelizabeth developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT randelljordan developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT kingbarbara developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT fernandezortegapaz developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT mcnamaramaireadg developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT kaltsasgregory developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT falconimassimo developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT cwiklajaroslav developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT capdevilajaume developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT grozinskyglasbergsimona developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT mandairdalvinder developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT gampereva developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT srirajaskanthanraj developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT oweickertmartin developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT graydebra developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule
AT developmentofaqualityoflifequestionnaireforpatientswithpancreaticneuroendocrinetumoursthepannetmodule